Treatment
Obinutuzumab clinical trials
We’re tracking 80 recruiting studies that include Obinutuzumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06849713RecruitingPhase 2
New combination treatments for CLL or SLL
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05197192RecruitingPhase 3
New treatment for high-risk CLL using two medicines plus chemo-free pills
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
Bad SaarowAges 18–120 - NCT05039619RecruitingPhase 2
Obinutuzumab trial for adolescents with active lupus kidney inflammation
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
Loma Linda, CaliforniaAges 5–17 - NCT05899621Recruiting
Study of obinutuzumab-based treatment for untreated follicular lymphoma
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT04908228RecruitingPhase 2
Fixed treatment with ibrutinib and obinutuzumab for untreated CLL
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
Milan, MIAges 18 years+ - NCT05786768RecruitingPhase 2/Phase 3
Obinutuzumab vs rituximab for relapsing childhood kidney syndrome
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
ParisAges 3–18 - NCT06454968RecruitingPhase 2
Combination therapy for first-line marginal zone lymphoma
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06513234RecruitingPhase 2
Orelabrutinib and Obinutuzumab for untreated marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
TianjinAges 18 years+ - NCT06566807RecruitingPhase 2
Orelabrutinib plus obinutuzumab for marginal zone lymphoma
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
Huai'an, JiangsuAges 18 years+ - NCT06553352RecruitingPhase 2
Zanubrutinib with obinutuzumab for new follicular lymphoma
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
Xiamen, FujianAges 18 years+ - NCT06592170RecruitingPhase 1/Phase 2
Linperlisib and obinutuzumab for new MZL
This trial tests a combination of two drugs for people newly diagnosed with marginal zone lymphoma (MZL). The goal is to see if the combination works better than standard treatments.
Changchun, JilinAges 18 years+ - NCT07746180RecruitingPhase 2
Obinutuzumab and low-dose steroids for new kidney disease
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
BeijingAges 18 years+ - NCT07719556RecruitingPhase 2
Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Changzhou, JiangsuAges 18 years+ - NCT07710157RecruitingPhase 2
Obinutuzumab for first episode of minimal change disease
This trial tests if obinutuzumab, a targeted therapy, can safely and effectively treat adults with their first episode of minimal change disease (MCD), a kidney condition causing protein leakage. Participants will receive the drug to see if it reduces protein in urine and improves symptoms.
GrazAges 18 years+ - NCT07611214RecruitingPhase 4
LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
La Mesa, CaliforniaAges 18–75 - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT07299149RecruitingPhase 2
Testing a new triple-drug combination for untreated follicular lymphoma
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT07268521RecruitingPhase 2
Obinutuzumab for cryoglobulinemia vasculitis after rituximab failure
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
BloisAges 18 years+ - NCT07261163RecruitingPhase 2
Combination therapy for first-line mantle cell lymphoma
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07218510RecruitingPhase 2
Venetoclax, obinutuzumab, then epcoritamab for untreated CLL/SLL
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
Duarte, CaliforniaAges 18 years+ - NCT07163611RecruitingPhase 2/Phase 3
Obinutuzumab for PLA2R antibodies in membranous nephropathy
This study is testing a drug called obinutuzumab to see if it can lower PLA2R antibodies in people with membranous nephropathy (a kidney disease). The goal is to reduce protein leakage in urine and improve kidney health.
NijmegenAges 18 years+ - NCT07126678Recruiting
Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Nanjing, JiangsuAges 18–75
What Obinutuzumab is being studied for
Conditions with recruiting Obinutuzumab studies.
Common questions
- Are there clinical trials studying Obinutuzumab?
- Yes. Clin2 currently lists 80 recruiting studies that include Obinutuzumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Obinutuzumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Obinutuzumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Obinutuzumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.